La médecine de précision redéfinit notre approche de la psychiatrie, notamment pour les troubles complexes comme l’autisme GrandAngle, Octobre 11, 2024 – Fondée en 2017 à Genève, STALICLA se distingue comme pionnière dans ce domaine. L’entreprise regroupe une trentaine de médecins chercheurs spécialisés en neuro-sciences et biologie moléculaire, opérant en Suisse, à Barcelone et à Boston. … Read more
LAUSANNE, Switzerland and SAN DIEGO, USA – Sept. 4, 2024 – HAYA Therapeutics, SA, a biotechnology company pioneering precision RNA-guided regulatory genome targeting therapeutics for chronic diseases, today announced a multi-year agreement with Eli Lilly and Company to apply HAYA’s advanced RNA-guided regulatory genome platform to support preclinical drug discovery efforts in obesity and related metabolic conditions. … Read more
Building on Existing Technologies for a Commercial Prototype Within a Decade Le directeur de la start-up genevoise estime que l’atome peut contribuer à lutter contre le réchauffement climatique tout en fournissant une quantité d’électricité extraordinaire. Transmutex veut réduire la durée de vie des déchets de 300 000 à 300 ans L’annonce jeudi du Conseil fédéral selon laquelle … Read more
LAUSANNE, Switzerland and SAN DIEGO – July 15, 2024 – HAYA Therapeutics, SA, a company developing RNA-guided programmable precision medicines focused on long non-coding RNAs (lncRNAs), today announced that Eric Adam, Ph.D. has joined as Chief Operating Officer (COO). With over 25 years of experience in health technology and healthcare sectors, Eric joins HAYA’s team in … Read more
Dr. Sarma brings exceptional expertise in all facets of the pharmaceutical and biotechnology business, from scaling platforms to developing therapeutics July 9, 2024 Geneva, Switzerland – July 9, 2024 – STALICLA SA, a Swiss neuro precision biotech company dedicated to developing precision medicine-based treatments for neurodevelopmental and neuropsychiatric disorders, such as autism spectrum disorder, announced today … Read more
Building on Existing Technologies for a Commercial Prototype Within a Decade A Swiss startup says it has pioneered a way to reduce radioactive waste from nuclear plants — which could help power data centers. Jason marz/1368745971/Getty Images Swiss startup Transmutex’s technology reduces long-term radioactive waste. The technology could further entice AI companies to use nuclear energy … Read more
Vincenzo Luciano Lucrezia, chief operating officer della società italiana specializzata in router e apparati di rete: “Grazie all’alleanza con Cysec offriamo valore aggiunto”. Il numero uno della cybercompany elvetica Patrick Trinkler: “Puntiamo allo sviluppo dello space internet che connetterà miliardi di persone” Antonello Salerno “Il comparto delle telecomunicazioni satellitari potrebbe essere una grande occasione, per l’Italia e … Read more
May 15 , 2024 Distalmotion, a pioneer in surgical robotics, proudly announces the achievement of a significant milestone: surpassing 1000 successful procedures with its surgical robot, Dexter. Since its first commercial installation in 2022, Dexter has become a cornerstone in surgical innovation, treating patients everyday across multiple countries and institutions. This milestone underscores the maturity … Read more
May 8, 2024 Geneva, Switzerland, May 8, 2024 – STALICLA SA, a Swiss neuro precision biotech company, has provided proof-of-concept clinical data for DEPI (Databased Endophenotyping Patient Identification), its neuro precision discovery platform, enabling the identification of biological subgroups of patients with Autism Spectrum Disorder (ASD) and matching treatments, in a study published last week in … Read more
STALICLA initiates U.S. Phase 3 enabling DDI study of STP7 (Mavoglurant) to treat cocaine use disorder May 2, 2024 Geneva, Switzerland, May 2, 2024 – STALICLA SA, a late-stage biotechnology company specializing in precision medicine for brain disorders, announces the First Patient First Visit (FPFV) for the company’s drug-drug interaction (DDI) study of STP7 (Mavoglurant), an … Read more
daniel bertholet
Copyright © 2024